Amedisys

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amedisys reports robust Q4 earnings, eyes growth amidst operational challenges

Amedisys showcases strong financial performance and strategic initiatives for 2023, focusing on growth and operational optimization.
Despite challenges like labor market issues and operational hurdles, the company remains confident in its growth strategies and talent management.
Opportunities in negotiations with payers, talent acquisition, and operational enhancements position Amedisys for continued success and revenue growth.
With a positive outlook for 2023 and a resilient approach to challenges, Amedisys is poised for steady growth and operational improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.

UnitedHealth Group

The DOJ suggests that UNH's acquisitions reflect a strategy of buying competitors rather than competing directly, potentially giving it control over multiple markets.

DOJ Lawsuit Questions UnitedHealth's $3.3 Billion Amedisys Deal

The Justice Department and three U.S. states filed a lawsuit on Tuesday to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc over concern the deal would harm competition in the market for home health services, the department said.

US sues to block UnitedHealth's $3.3 bln purchase of Amedisys

The U.S. Justice Department is moving to block UnitedHealth Group's $3.3 billion purchase of Amedisys Inc. over concerns the deal would harm competition in the market for home health services, Bloomberg News reported on Tuesday, citing people familiar with the matter.

US Justice Department preps suit over UnitedHealth-Amedisys deal, Bloomberg News reports

Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.

AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say

Amedisys (AMED) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $0.98 per share a year ago.

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024.

Amedisys Reports Third Quarter 2024 Financial Results

Chemed

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?

AMED or CHE: Which Is the Better Value Stock Right Now?

Addus HomeCare

Quest Diagnostics

Encompass Health

Dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, AMED and ADUS are well-poised to gain.

4 Stocks to Buy in an Evolving Outpatient Home Health Industry

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Amedisys (AMED) Beat Estimates Again in Its Next Earnings Report?

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two stocks is more attractive to value investors?

AMED vs. CHE: Which Stock Is the Better Value Option?

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade

BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program.

Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards

Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination, Support for Caregivers Guiding an Improved Dementia Experience (GUIDE) Model Aims to Increase Care Coordination, Support for Caregivers

Contessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care Model

U.S. Physical Therapy

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Amedisys (AMED) or U.S. Physical Therapy (USPH). But which of these two stocks is more attractive to value investors?

AMED vs. USPH: Which Stock Is the Better Value Option?

Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.

Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down

The headline numbers for Amedisys (AMED) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Amedisys (AMED) Q2 Earnings: A Look at Key Metrics

Amedisys (AMED) came out with quarterly earnings of $1.32 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.37 per share a year ago.

Amedisys (AMED) Q2 Earnings and Revenues Top Estimates

BATON ROUGE, La., July 24, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2024.

Amedisys Reports Second Quarter 2024 Financial Results

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why Amedisys (AMED) is a Strong Momentum Stock

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?

AMED or USPH: Which Is the Better Value Stock Right Now?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Amedisys (AMED) is a Strong Value Stock

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two stocks is more attractive to value investors?

News for Amedisys Stock (AMED)